Skip to main content
. 2020 Jul 29;8(2):e000417. doi: 10.1136/jitc-2019-000417

Figure 5.

Figure 5

MC38-OVA tumor analysis demonstrates enhanced T cell function associated with tumor efficacy by AZD4635 in combination with anti-PD-L1. (A–I) Single cell suspension of MC38-OVA tumors were prepared and stimulated with PMA/ionomycin. CD8+ T cells as a percentage of CD3+, CD45+ cells were analyzed for (A). Interferon (IFN)-γ production (B). Tumor necrosis factor (TNF)-α (C). Interleukin (IL)-2 (D). Granzyme B (E). CD107a expression. CD4+ T cells were analyzed for (F). IFN-γ production (G). TNF-α (H). IL-2 (I). NK cells determined as CD3-, NKp46+ as a percentage CD45+ tumor-infiltrating lymphocyte (TIL) were analyzed for IFN-γ production (J, K). NK cells were analyzed for TNF-α production and CD107a expression, respectively (L, M). Tumor draining lymph node cells from MC38-OVA tumor-bearing mice were stimulated with OVA and p15E peptide (1 μg/mL) and IFN-γ production was analyzed using ELISpot assay. Data are representative of TIL analysis from three repeated efficacy studies with similar results (n=6), stained with antibodies to lymphoid and myeloid antigens as indicated in online supplementary figure 3. *P<0.05, **p<0.01, ***p<0.001 (Mann-Whitney U test).